Brief Title: DESTINY-PANTUMOUR04

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Real world response rate (rwRR)

Primary Outcome 1 - Timeframe: Through study completion

Primary Outcome 2 - Measure: Real world duration of response (rwDoR)

Primary Outcome 2 - Timeframe: up to 2.5 years after enrolment

CONDITION

• Adenocarcinoma (NOS)
• Anal Cancer
• Bladder Cancer
• Cervical Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gall Bladder Cancer
• Gastrointestinal Stromal Tumour
• Head and Neck Cancer
• Liver Cancer
• Melanoma
• Mouth Cancer
• Nasopharangeal Cancer
• Neuroendocrine
• Gastrointestinal Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer
• Renal Cell Carcinoma
• Salivary Gland Cancer
• Sarcoma
• Small Cell Lung Cancer
• Testicular Cancer
• Throat Cancer
• Thyroid Cancer
• Urethral Cancer
• Vaginal Cancer
• Vulvar Cancer

ELIGIBILITY

Inclusion Criteria:
1. Adults aged ≥18 years

- 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);

- 3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;

- 4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;

- 5. Patients who are willing and able to provide a signed and dated informed consent.
Exclusion Criteria:
1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;

- 2. Prior T-DXd therapy;

- 3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.

- 4. Patient is participating in a clinical trial at time of enrolment

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: AstraZeneca Clinical Study Information Center

Phone: 1-877-240-9479

Email: [email protected]

LOCATION